Session Abstract – PMWC 2025 Silicon Valley
Speaker Profile
Biography
Gudrun specializes in developing advanced genomics platforms, drawing on her experience in NGS development and background in biophysics and biochemistry. She has made significant contributions to the field, including the development of the NovaSeq platform at Illumina, and the Aviti platform at Element. In the startup space, she played a key role in securing Series B funding for Encodia through her work in proteomics. Currently, as the founder of Alida Biosciences, Gudrun is focused on creating novel RNA epitranscriptomic technologies designed to advance beyond primary transcriptomic sequence analysis, to empower a new frontier of RNA biology and enhancement of multi-omic studies.
Talk
RNA Beyond Primary Sequence: Introducing Multiplexed Epitranscriptomics
AlidaBios EpiPlex revolutionizes RNA modification profiling with high-throughput, multiplexed detection. Our approach integrates advanced library preparation with machine-learning powered bioinformatics and NGS readout, enabling quantifiable, scalable, and accessible multiomic insights. EpiPlex paves the way for personalized medicine by revealing disease-specific RNA modification patterns, making it a vital tool for precision health and multiomic studies.
Spatial Showcase:
Alida Biosciences
AlidaBio is commercializing accessible tools that broaden the application of epitranscriptomics in life sciences. Our groundbreaking products EpiPlex™ and EpiScout™ empower researchers to concurrently analyze multiple RNA modifications with relative quantification, using RNA inputs suitable for clinically relevant samples and supported by user-friendly bioinformatics.
Speaker Profile
Biography
Dr. Libermann is an internationally recognized translational investigator with a strong track record in precision medicine, biomarker discovery and translational studies of cancer, neurological and immunological diseases. His lab is focused on applying proteomics approaches to identify proteins that may be exploited as biomarkers or targets for therapeutic intervention, starting with his seminal discovery of EGF receptor gene amplifications in glioblastomas. Dr. Libermann has been at the forefront of next generation proteomics and plays a central role in driving biomarker discovery to the next level. Libermanns group uses the aptamer-based SomaScan proteomics platform to discover and validate diagnostic, predictive, and prognostic biomarkers for various diseases using liquid biopsies such as extracellular vesicles and body fluids. Using the latest in machine learning, Libermanns group has developed predictor models for applications in early detection, disease diagnosis, prediction of therapeutic response, monitoring of disease progression, and outcome prediction.
Talk
Accelerating Precision Medicine With Aptamer-Based 11k SomaScan Proteomics
Novel proteomics platforms have been developed to drive precision medicine and biomarker discovery. We will present our efforts on non-invasive and tissue biomarkers for a broad range of clinically highly relevant diagnostic, predictive, and prognostic indications using the currently most comprehensive, high throughput proteomics platform, SomaScan v5.0, measuring 11,000 proteins.
Spatial Showcase:
Harvard Medical School
Beth Israel Deaconess Medical Center in Boston, Massachusetts is a teaching hospital of Harvard Medical School. It was formed out of the 1996 merger of Beth Israel Hospital and New England Deaconess Hospital.
Speaker Profile
Biography
Joel J. Credle, Ph.D., is a co-founder of Infinity Bio and serves as its Director of Research and Development. With over 15 years of molecular biology experience, he specializes in developing high-plex next-generation assays at Infinity Bio. His innovations include MIPSA, a molecular display technology, which creates synthetic DNA-barcoded antigen peptide andor ORFeome-scale libraries of full-length proteins to deeply characterize antibody reactivies. At Infinity Bio, he leads RD efforts to develop new MIPSA libraries including HuSIGHT, which covers the entire human proteome with full-length proteins and peptides for most comprehensive detection of autoantibodies. Dr. Credle earned his Ph.D. from Georgetown University and completed postdoctoral training with Dr. H. Benjamin Larman in the Laboratory for Precision Immunology at Johns Hopkins University School of Medicine.
Talk
Measuring the Circulating Antibody Reactome for Translational Biomarker Research
Infinity Bio is the antibody reactome profiling company. Our technology translates the antibody reactome, the set of all possible antibody-antigen binding interactions. We add a crucial dimension to multiomics studies by detecting antibodies targeting all known human-infecting viruses, and self-proteins, thus enabling the identification of novel biomarkers and disease mechanism.
Spatial Showcase:
Infinity Bio
Infinity Bio leverages an antigen display technology for antibody reactome profiling and comprehensively measures the repertoire of reactivities against the entire human proteome or virome. Identifying pre-existing or de-novo (auto) antibody reactivities could reveal novel biomarkers of disease and clinical outcomes.